07:00 , May 11, 2015 |  BioCentury  |  Politics, Policy & Law

Transparency scorecard

Three state transparency bills that attempted to force disclosure of biopharmaceutical product development and marketing costs have withered on the vine. But industry certainly isn't in the clear yet, with two more bills in state...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Clinical News

Rociletinib: Phase I/II data

Data from 27 evaluable NSCLC patients with the T790M EGFR resistance mutation in a Phase I/II trial showed that twice-daily 500 and 625 mg oral rociletinib led to an ORR of 67%, a disease control...
08:00 , Dec 8, 2014 |  BioCentury  |  Finance

Polaris hunts problems and solutions

With a fresh $450 million in hand, Polaris Partners plans to stick with an investment strategy that balances bets on big innovations with growth equity plays. The firm last week closed its oversubscribed seventh fund,...
08:00 , Nov 3, 2014 |  BioCentury  |  Finance

Fresh fund, same plan

Advent Venture Partners plans to stick with its long-standing investment strategy for its second dedicated life sciences fund, Advent Life Sciences Fund II, which the firm closed last week with £145.5 million ($234.3 million). "The...
07:00 , Oct 6, 2014 |  BioCentury  |  Finance

Atlas' next chapter

After separating from the tech group, Atlas Venture 's healthcare team plans to stick to the early stage investing strategy the firm says has provided returns in the top quartile of life science VCs. For...
07:00 , Oct 2, 2014 |  BC Innovations  |  Strategy

Progressive thinking in MS

Despite the slew of treatments that have entered the market in the last few years for relapsing-remitting multiple sclerosis, there have been few advances in the progressive form of the disease, largely because there is...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

CO-1686: Phase II started

Clovis began the open-label, international, pivotal Phase II TIGER2 trial to evaluate 625 mg oral CO-1686 twice daily in 28-day cycles in 125 patients with T790M-positive NSCLC who progressed after their first and only tyrosine...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Company News

Editas Medicine management update

Editas Medicine , Cambridge, Mass.   Business: Gene/Cell therapy   Hired: Katrine Bosley as CEO, formerly CEO of Avila Therapeutics Inc. , which Celgene Corp. acquired; she succeeds interim President Kevin Bitterman, who remains a...
00:24 , Jun 25, 2014 |  BC Extra  |  Company News

Editas names Bosley CEO

Genome editing company Editas Medicine (Cambridge, Mass.) hired Katrine Bosley as CEO. She was CEO of Avila Therapeutics Inc. , which Celgene Corp. (NASDAQ:CELG) acquired in 2012. Bosley succeeds Kevin Bitterman, a partner at Editas...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Clinical News

AVL-301: Additional Phase I/II data

Clovis reported additional data from 81 evaluable patients treated with CO-1686 at efficacious doses - defined as twice-daily 900 mg doses of the free base capsule formulation or any dose of the hydrobromide salt tablet...